Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsIn the randomized Phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for TNBC improved progression-free survival, particularly in patients with PIK3CA/AKT1/PTEN-altered tumors.
[Clinical Cancer Research]
Home Newsletters Mammary Cell News Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic...
